---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-25-000089"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:47:19.288433+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q3 net loss $14.2M; cash $184.2M after $50M PIPE; ALTO-207 on track for Phase 3 by early 2027

## Summary
- Net loss $14.2M vs $16.8M in Q3 2024; R&D expense $10.5M, G&A $4.4M.
- Cash $184.2M as of Oct 31 (incl. $49.9M net PIPE proceeds), projected to fund operations into 2028.
- ALTO-207 Phase 2b TRD trial start 1H 2026; Phase 3 by early 2027 after successful FDA meeting.
- Topline data expected: ALTO-101 CIAS (1Q 2026), ALTO-300 MDD (mid-2026), ALTO-100 BPD (2H 2026).
- ALTO-101 granted FDA Fast Track Designation for CIAS; blinded PK analyses showed 100% positivity.

## SEC filing metadata
- accession: 0001999480-25-000089
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/0001999480-25-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/alto-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-25-000089
- JSON: https://secwatch.observer/filing/0001999480-25-000089.json
- Plain text: https://secwatch.observer/filing/0001999480-25-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.